Items Tagged ‘Gazyva’

December 15th, 2016

Gazyva® Improves Outcomes Compared to Rituxan® in Untreated Follicular Lymphoma

By

Treatment including the targeted agent Gazyva (obinutuzumab) delays cancer progression for a longer period of time than treatment with Rituxan (rituximab) among patients with follicular lymphoma who have not received prior therapy. These results were recently presented at a plenary session of the 2016 annual meeting of the American Society of Hematology (ASH). Follicular lymphoma […]

View full entry

Tags: ASH 2016, B-cells, FL, Follicular Lymphoma, GALLIUM trial, Gazyva, News, Non-Hodgkin's Lymphoma, obinutuzumab, rituxan, rituxumab


June 8th, 2016

Gazyva® Showed Superior Progression-Free Survival Compared to Rituxan® in Follicular Lymphoma

By

Genentech, announced positive results from the pivotal Phase III GALLIUM study in people with previously untreated follicular lymphoma, the most common type of indolent (slow-growing) non-Hodgkin’s lymphoma (iNHL). The study compared Gazyva® (obinutuzumab) plus chemotherapy (CHOP, CVP or bendamustine) followed by Gazyva alone, head-to-head with Rituxan® (rituximab) plus chemotherapy followed by Rituxan alone. Results from […]

View full entry

Tags: Follicular Lymphoma, GALLIUM study, Gazyva, iNHL, News, nhl, Non-Hodgkin's Lymphoma, non-Hodgkin’s, rituxan, rituximab